INTRODUCTION

*Vibrio* (V.) spp. are halophilic rod-shaped bacteria found in marine waters [1]. Of the approximately 100 known *Vibrio* species at least twelve have been linked to human infections [1]. Strains belonging to the serogroups non-O1/non-O139 of *V. cholerae* are the causative agent of cholera, an epidemic diarrheal disease which still is a great public health problem in many developing countries. Other human pathogenic *Vibrio* isolates (designated as non-cholera *Vibrio* spp.) mainly can cause gastrointestinal infections and wound infection infections. *V. vulnificus* in particular is a feared pathogen causing severe wound infections and bacteremia with high mortality [2]. Other non-cholera *Vibrio* spp. seem to be less virulent than *V. vulnificus*. Wound infections have been described after infection with *V. parahaemolyticus*, *V. alginolyticus* [1] and *V. harveyi* [3].

Although located at high latitude, the Baltic Sea offers long stretches of shallow coastal regions, where water temperature in summer allows growth of *Vibrio* spp. Already in 1992 *V. anguillarum* has been isolated from the Baltic Sea [4]. Later on, *V. alginolyticus*, *V. cholerae* (non-O1 and non-O139), *V. mimicus*, *V. parahaemolyticus* and *V. vulnificus* have been found in brackish waters of the Baltic Sea [5–7] and *V. diazotrophicus* in deep subsurface sediments [8].

*Vibriosis*, severe wound infections and septicemias after contact with the Baltic Sea have been described mainly for *V. vulnificus* e.g. [9]. Less severe infections with *V. parahaemolyticus* and non-O1/non-O139 *V. cholerae* are increasingly being observed around the Baltic Sea [10, 11]. *V. fluvialis* has been recognized as an emergent pathogen mainly causing diarrhoea. Single reports of bacteremia, endophthalmitis, cholangitis and cerebritis have been reviewed [12]. *V. fluvialis* has been retrieved from marine sources in Asia, America, Africa and from the Mediterranean Sea [12] but to our knowledge rarely from the Baltic Sea. We describe the first
isolation of \textit{V. fluvialis} from a wound infection acquired by an impalement injury caused by penetration of an extremity (foot) with a piercing object.

**CASE REPORT, TREATMENT AND OUTCOME**

On 4 August 2019, a male patient (49 years old) dismounted his surfboard in the shallow waters of the strait between Stralsund and the island of Rügen. He stepped onto an unknown piercing object and suffered an impalement injury of his left foot. The water temperature in Kramerhof (close to Stralsund) had been reported as 21 °C on August 4th after a sunny period of warm days with temperature highs of around 25 °C.

In our hospital the heavily contaminated wound between the second and third metatarsal bones was cleaned. After debridement a wick was inserted. Standard antibiotic therapy was initiated with ampicillin/sulbactam 3 g three times a day, i.v. Because of presumed uncomplicated wound conditions, no swabs for microbiological investigations were taken.

Due to an increasing infection the soft tissue the wound was revised on day 6. After debridement negative pressure wound therapy was applied. A swab taken from the phlegmonous tissue grew \textit{V. fluvialis} on day 8. The initial antibiotic susceptibility testing showed sensitivity to ampicillin/sulbactam, thus therapy was continued. When changing the negative pressure wound therapy on day 9, a drastic worsening was noticed. Intensive debridement had to be performed and thereafter polihexanid lavasorb bandage was applied. Due to the worsened infection antibiotic therapy was switched to ceftriaxone and ciprofloxacin to combat the bacterial infection. The biopsies taken during surgery grew \textit{Enterobacter cloacae} and \textit{Proteus vulgaris} on day 10 of which only \textit{P. vulgaris} was intermediate susceptible to ampicillin/sulbactam acid. Both isolates were sensitive to ciprofloxacin. On day 10 the amputation of the third toe became necessary due to massive bone and soft tissue necrosis. After amputation the clinical situation improved, and the patient left the hospital on day 17. Ceftriaxone i.v. was discontinued on day 12, oral ciprofloxacin therapy ended on day 18.

**Microbiological diagnosis**

Colonies derived from the phlegmonous soft tissue during the first wound revision were grown on sheep blood agar and identified by matrix-assisted-laser-desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) as \textit{V. fluvialis}. Antibiotic susceptibility testing (EUCAST) had been done in Vitek 2 (Biomérieux) at first and revealed an isolate widely sensitive to ampicillin, ceftriaxone, ceftazidime, ciprofloxacin, trimethoprim/sulfamethoxazole and doxycycline.

However, the antibiotic susceptibility testing of the \textit{V. fluvialis} isolate was repeated later with the standard Kirby–Bauer disc diffusion method following Clinical and Laboratory Standards Institute (CLSI) guidelines. The isolate was found to be resistant to 10 μg per disc of ampicillin, and sensitive (μg per disc) to ceftriaxone (30), ciprofloxacin (5), chloramphenicol (30), trimethoprim/sulfamethoxazole (1.25/23.75), tetracycline (30) and gentamicin (30). The isolate was sent to the Vibrio reference laboratory at the German Federal Institute for Risk Assessment for species confirmation and was confirmed as \textit{V. fluvialis} by using MALDI-TOF MS. A number of phenotypical tests were carried out and showed the expected results for the species (according to ISO standard 21872-2 : 2006). The isolate 19-VB00936 was oxidase-positive and required NaCl for growth in 1% peptone water (PW). Colonies on thiosulfate-citrate-bile salts (TCBS) agar were yellow and no production of gas from glucose fermentation was observed (discrimination to the species \textit{V. furnissii}). Lysine-decarboxylase and ornithine-decarboxylase tests were negative and arginine-dihydrolase test positive. Fermentation of sucrose was positive and for lactose negative, ONPG hydrolysis was positive.

**Molecular characterization**

A conventional \textit{toxR} PCR for species determination of \textit{V. fluvialis} was performed [13] and yielded a PCR product with the expected size. Finally, sequence analysis of an 871 bp fragment of the coding region of the \textit{rpoB} gene was carried out which is a valuable tool for species identification [14–16]. The obtained sequence revealed identity to several \textit{V. fluvialis} \textit{rpoB} sequences of more than 99%.

Moreover, the isolate was subjected to whole genome sequencing for further investigation. Therefore, the isolate was cultivated for 24 h at 37 °C in lysogeny broth. Genomic DNA was extracted using the PureLink Genomic DNA Mini Kit (Thermo Fisher Scientific, Waltham, MA, USA) and sequenced using Illumina short-read (Illumina, San Diego, CA, USA) and Oxford Nanopore Technologies (ONT, Oxford, UK) long-read sequencing platforms.

An Illumina sequencing library was prepared using the Nextera DNA Flex Kit. Paired-end sequencing was performed in 2×151 bp cycles on an Illumina iSeq instrument using the iSeq 100 ii Reagent v1 Kit (300-cycle). An ONT sequencing library was prepared using the Rapid Barcoding Kit and sequenced on an ONT MinION Mk1C sequencer using a Flongle adapter and a Flongle flowcell (FLO-FLG001).

Illumina short-reads were trimmed using fastp v0.19.5 [17]. ONT long-reads were trimmed using Porechop v0.2.3 (https://github.com/rrwick/Porechop), filtered using NanoFilt v2.7.1 and quality checked using NanoStat v1.4.0 [18]. Illumina and ONT reads were combined in a hybrid assembly using Unicycler v0.4.8 including Pilon [19–21].
The assembly resulted in two circular bacterial chromosomes chr_1 (3237604 bp) and chr_2 (1570538). The overall G+C content of the bacterial genome was 50.1%. The genome sequence was deposited in the NCBI nucleotide database. Search for antimicrobial resistance (AMR) genes and point mutations was conducted using AMRFinderPlus v3.10.1 with database version 2021-03-01 [22]. No AMR genes or point mutations associated with AMR could be detected. The genome sequence was uploaded to the PATRIC Bioinformatics Resource Centre [23]. The closest reference genome to 19-VB00936 was identified using the Similar Genome Finder Tool searching the reference and representative genomes database. The closest reference identified was *Vibrio fluvialis* strain ATCC 33809 (FDAARGOS_104, NCBI BioSample: SAMN03996321) isolated from a patient from Bangladesh suffering from a *Vibrio* infection. The two genome sequences were compared using the ANI calculator from Kostas lab (http://enve-omics.ce.gatech.edu/ani/index). An Average Nucleotide Identity (ANI) of 98.46% was calculated.

**DISCUSSION**

*Vibrio* spp. need water temperatures of around 20 °C to promote growth [7]. Thus, growth of *Vibrio* and infections thereof are frequently encountered in warm equatorial oceans [1]. The Baltic Sea is located at a relatively high latitude with freezing temperatures in some winters. Nevertheless, *Vibrionaceae* have been described as early as 1992 in the Baltic Sea [4]. Even more, due to climate change a warming trend is evident in the Baltic region [24] and an increasing number of reports have shown a rising number of severe infections with *V. vulnificus* in shallow coastal regions of the Baltic Sea in warm summers [9, 10].

We report a soft tissue infection with *V. fluvialis* after an impalement injury acquired in the Baltic Sea. To our knowledge, this is the first reported wound infection with of *V. fluvialis* in the Baltic Sea. *V. fluvialis* infections generally seem to be less severe than infections with *V. vulnificus* [1, 12], however, wound infections have been described in case reports from Taiwan [25] and the USA [26].

If *V. fluvialis* in our case report only caused a soft tissue infection or was paramount to the development of bone infections and necrosis leading to amputation of the third toe remains elusive. *V. fluvialis* was the only bacterium identified after 7 days of antibiotic therapy. However, materials retrieved while amputating the third toe only gave growth to *P. mirabilis* and *E. cloacae*.

What can be learnt from this case report? The standard therapy with ampicillin/sulbactam was suboptimal to cure the heavily contaminated wound. In hindsight, therapy of a deep-seated infection acquired in shallow waters of the Baltic Sea in a particularly hot season was not adequate. *V. fluvialis* is the first reported wound infection with a *Vibrio* species in coastal waters. In warm summers, *V. fluvialis* infections generally seem to be less severe than infections with *V. vulnificus* [1, 12], however, wound infections have been described in case reports from Taiwan [25] and the USA [26].

The assembled genome sequence of the *V. fluvialis* strain was uploaded to the ENA database (stn:7566208). AMR resistance (AMR) genes and point mutations was conducted using AMRFinderPlus v3.10.1 with database version 2021-03-01 [22]. No AMR genes or point mutations associated with AMR could be detected. The genome sequence was uploaded to the PATRIC Bioinformatics Resource Centre [23]. The closest reference genome to 19-VB00936 was identified using the Similar Genome Finder Tool searching the reference and representative genomes database. The closest reference identified was *Vibrio fluvialis* strain ATCC 33809 (FDAARGOS_104, NCBI BioSample: SAMN03996321) isolated from a patient from Bangladesh suffering from a *Vibrio* infection. The two genome sequences were compared using the ANI calculator from Kostas lab (http://enve-omics.ce.gatech.edu/ani/index). An Average Nucleotide Identity (ANI) of 98.46% was calculated.

**Funding information**

The authors received no specific grant from any funding agency.

**Author contributions**

CRediT: 1 E.F.; 3 M.B.; 5 W.G., J.N.; E.S., St.S.; 8 J.H., S.D.; 10 B.F., E.S.; 13 I.K.; E.S., St.S., M.B.

**Conflicts of interest**

The authors declare that there are no conflicts of interest.

**Ethical statement**

Written consent was obtained from the patient for publishing this data.

**References**

1. Baker-Austin C, Oliver JD, Alam M, Ali A, Waldor MK, et al. *Vibrio* spp. infections. *Nat Rev Dis Primers* 2018;4:8.

2. Baker-Austin C, Oliver JD. *Vibrio vulnificus*: new insights into a deadly opportunistic pathogen. *Environ Microbiol* 2018;20:423–430.

3. Brehm TT, Berneking L, Rohde H, Chistner M, Schlickewei C, et al. Wound infection with *Vibrio harveyi* following a traumatic leg amputation after a motorboat propeller injury in Mallorca, Spain: a case report and review of literature. *BMC Infect Dis* 2020;20:104.

4. Gierer W, Rabsch W, Reissbrodt R. Siderophore pattern of fish-pathogenic *Vibrio anguillarum* *Aeromonas* spp. and *Pseudomonas* spp. from the German Baltic coast. *Journal of Fish Diseases*. 1992;15:417–23.

5. Bier N, Schwartz K, Guerra B, Strauch E. Survey on antimicrobial resistance patterns in *Vibrio vulnificus* and *Vibrio cholerae* non-O1/non-O139 in Germany reveals carbapenemase-producing *Vibrio cholerae* in coastal waters. *Front Microbiol* 2015;6:1179.

6. Jones J, Stephan R, Knabner D, Gelderblom HR, Lewin A. Isolation of *Vibrio vulnificus* and atypical *Vibrio* from surface water of the Baltic Sea in Germany. *Berl Munch Tierarztl Wochenschr* 2003:116:396–400.

7. Semenza JC, Trinanes J, Lohr W, Sudre B, Löfdahl M, et al. Environmental suitability of *Vibrio* infections in a warming climate: an early warning system. *Environ Health Perspect* 2017;125:10.

8. Castillo D, Vandieken V, Engelen B, Engelhardt T, Middelboe M. Draft genome sequences of six *Vibrio diazotrophicus* strains isolated from deep subsurface sediments of the Baltic Sea. *Genome Announc* 2018;6:10.

9. Metelmann C, Metelmann B, Gründling M, Hahnenkamp K, Hauk G, et al. *Vibrio vulnificus*, an increasing threat of sepsis in Germany? *Anaesthesist* 2020;69:672–678.
10. Baker-Austin C, Trinanés JA, Salmenlinna S, Löfdahl M, Siitonen A, et al. Heat wave-associated *Vibriosis*, Sweden and Finland, 2014. *Emerg Infect Dis* 2016;22:1216–1220.

11. Huehn S, Eichhorn C, Urmersbach S, Breidenbach J, Benchars S, et al. Pathogenic vibrios in environmental, seafood and clinical sources in Germany. *Int J Med Microbiol* 2014;304:843–850.

12. Ramamurthy T, Chowdhury G, Pazhani GP, Shinoda S. *Vibrio fluvialis*: an emerging human pathogen. *Front Microbiol* 2014;5:91.

13. Chakraborty R, Sinha S, Mukhopadhyay AK, Asakura M, Yamasaki S, et al. Species-specific identification of *Vibrio fluvialis* by PCR targeted to the conserved transcriptional activation and variable membrane tether regions of the toxR gene. *J Med Microbiol* 2006;55:805–808.

14. Mollet C, Drancourt M, Raoult D. rpoB sequence analysis as a novel basis for bacterial identification. *Mol Microbiol* 1997;26:1005–1011.

15. Schirmeister F, Wieczorek A, Dieckmann R, Taureck K, Strauch E. Evaluation of molecular methods to discriminate the closely related species *Vibrio fluvialis* and *Vibrio furnissii*. *Int J Med Microbiol* 2014;304:851–857.

16. Tarr CL, Patel JS, Puhr ND, Sowers EG, Bopp CA, et al. Identification of *Vibrio* isolates by a multiplex PCR assay and rpoB sequence determination. *J Clin Microbiol* 2007;45:134–140.

17. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics* 2018;34:i884–i890.

18. De Coster W, D’Hert S, Schultz DT, Cruts M, Van Broeckhoven C. NanoPack: visualizing and processing long-read sequencing data. *Bioinformatics* 2018;34:2666–2669.

19. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads. *PLoS Comput Biol* 2017;13:e1005595.

20. Wick RR, Judd LM, Gorrie CL, Holt KE. Completing bacterial genome assemblies with multiplex MinION sequencing. *Microb Genom* 2017;3:e000132.

21. Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, et al. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. *PLoS One* 2014;9:e112963.

22. Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, et al. Validating the AMRFinder tool and resistance gene database by using antimicrobial resistance genotype-phenotype correlations in a collection of isolates. *Antimicrob Agents Chemother* 2019;63:e00483-19.

23. Davis JJ, Wattam AR, Aziz RK, Brettin T, Butler R, et al. The PATRIC Bioinformatics Resource Center: expanding data and analysis capabilities. *Nucleic Acids Res* 2020;48:D606–D612.

24. Andersson A, Meier HEM, Ripszam M, Rowe O, Wikner J, et al. Projected future climate change and Baltic Sea ecosystem management. *Ambio* 2015;44 Suppl 3:345–356.

25. Huang K-C, Hsu RW-W. *Vibrio fluvialis* hemorrhagic cellulitis and cerebritis. *Clin Infect Dis* 2005;40:e75-7.

26. Varghese MR, Farr RW, Wax MK, Chafin BJ, Owens RM. *Vibrio fluvialis* wound infection associated with medicinal leech therapy. *Clin Infect Dis* 1996;22:709–710.

27. Horsemah MA, Surani S. A comprehensive review of *Vibrio vulnificus*: an important cause of severe sepsis and skin and soft-tissue infection. *Int J Infect Dis* 2011;15:e157-66.